Menu

EMA issues reflection paper for follow-on versions of iron-based nano-colloidal products

Fármacos complejos no biológicos/Directrices | Posted 05/11/2015 post-comment0 Post your comment

On 27 March 2015, the European Medicines Agency (EMA) published its reflection paper for follow-on versions of iron-based nano-colloidal products. The agency first released the draft reflection paper for follow-on versions of iron-based nano-colloidal products for a three-month consultation period in September 2013.

24-AA011041

EMA tends to refer to biosimilars regulations when considering ‘follow-on’ versions of non-biological complex drugs (NBCDs), such as iron carbohydrate complexes, liposomal drugs and glatiramoids.

Like biologicals, NBCDs consist of different (closely related) structures that cannot be fully quantitated, characterized or described by (physico-)chemical analytical tools. The composition and quality of NBCDs are dependent on the manufacturing process and controls – just as is the case with biologicals. Therefore, approval of follow-on NBCDs via generics pathways may not be appropriate and use of biosimilars pathways for non-biologicals is also not appropriate.

Via this reflection paper, which is available on the EMA website, EMA sets out additional data requirements for follow-on versions of iron-based nano-colloidal products used to treat iron deficiency. These extra requirements have been based on the fact that quality characterization on its own would not provide sufficient assurance of the similarity between the follow-on version and the originator product, even if the quality tests performed show similarity. In the context of such iron-based preparations, EMA has decided that a ‘weight of evidence approach’ including data from quality, non-clinical and human pharmacokinetic studies is required.

Reflection paper on follow-on versions of iron-based nano-colloidal products
Date: 26 March 2015
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184922.pdf

EMA has also adopted a reflection paper for intravenous liposomal products [1].

Related articles
EU guidelines for biosimilars

EU guidelines for generics

Reference
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for follow-on NBCDs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Nov 6]. Available from:
www.gabionline.net/Non-Biological-Complex-Drugs/Reports/Regulations-for-follow-on-NBCDs

Source: EMA

comment icon Comments (0)
Post your comment
Novedades

FDA approves 40 mg follow-on version of glatiramer acetate

Mylan launches first follow-on glatiramer acetate in the UK

Foro latinoamericano
Español
map logo
Investigación

Biosimilars and follow-on NBCDs for MS in Europe, the US and Canada

Challenges in the regulation of NBCDs

Most viewed articles

Sobre GaBI

The best selling biotechnology drugs of 2008: the next biosimilars targets

Global biosimilars guideline development – EGA’s perspective

EU guidelines for biosimilars

Related content
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
The best selling biotechnology drugs of 2008: the next biosimilars targets
picture09
INICIO/Informes Posted 14/10/2009
Global biosimilars guideline development – EGA’s perspective
picture07
INICIO/Directrices Posted 28/09/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010